Therapeutic Plasma Exchange

Use the CRRT machine you trust to deliver mTPE to your patients.

Expand Your Treatment Offering

PRISMAX/PRISMAFLEX Systems offer a simple, efficient and cost-effective alternative to centrifugation-based TPE systems.

Studies have shown membrane Plasma Exchange (mTPE) to be similarly safe and effective compared to centrifugation (cTPE)^1-6
May be significantly more cost effective than contracted mobile apheresis services⁷
THOUSANDS of procedures performed each year in the US⁷
90% of plasmapheresis treatments are performed by membrane plasma separation in some countries⁷

What is mTPE?

Membrane therapeutic plasma exchange (mTPE) is performed with a highly permeable filter and dialysis equipment. mTPE on a PRISMAFLEX or PRISMAX System is achieved with simultaneous infusion of a replacement solution. Plasma is removed and pumped through the large-pore membrane of the plasma filter, while a colloid solution, such as albumin and/or plasma, or a combination of crystalloid/colloid solution, is infused post-plasma filter to replace the removed plasma.

The disposable TPE 2000 Set is the only extra part needed to run TPE on a PRISMAX or PRISMAFLEX System.

Keeps You in Control

Reduce Delays and Referrals: Initiate therapy rapidly and help maintain control over your patients’ care.

Manage Equipment: Hospitals that already own a PRISMAX System can run TPE without purchasing an additional machine.

Decrease Maintenance: Only one machine to be maintained for multiple therapies, potentially decreasing maintenance costs.

Streamline Training: Set-up and execution is similar to CRRT procedure set-up, so nurses may find training is similar.

Featured Presentation:

Therapeutic Plasma Exchange Part I: Methods, Goals & Guidelines

In this 2-part series, Tena Griffin covers apheresis methods and goals of treatment, as well as TPE selection criteria, planning and factors influencing dose and schedule.

Watch Now

The PRISMAFLEX and PRISMAX Systems are intended for:
Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload.

Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where fluid removal of plasma components is indicated.

Rx Only. For safe and proper use of products mentioned herein refer to the appropriate Instructions for Use or Operator's Manual.

PHOXILLUM and PRISMASOL Renal Replacement Solution Indications and Important Risk Information

Indications and Usage
PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.

Warnings and Precautions
Electrolyte and Volume Abnormalities
PHOXILLUM and PRISMASOL solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately. PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis.

Blood Glucose Abnormalities
The use of PRISMASOL and PHOXILLUM replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. Patients may require initiation of or modification of antidiabetic therapy or other corrective measures during treatment.

Please see PHOXILLUM and PRISMASOL Solutions full Prescribing Information.

MARS is indicated for the treatment of drug overdose and poisonings. The only requirement is that the drug or chemical be dialyzable (in unbound form) and bound by charcoal and/or ion exchange resins.

MARS is not indicated for the treatment of chronic liver disease conditions or as a bridge to liver transplant. Safety and efficacy has not been demonstrated for those indications in controlled, randomized clinical trials. The effectiveness of the MARS device in patients that are sedated could not be established in clinical studies and therefore cannot be predicted in sedated patients.

References:

Gurland HJ, Lysaght MH, Samtleben W, Schmidt B. Int J Artif Organs.1984;7:35-38.
Gurland HJ, Lysaght MJ, Samtleben W, Schmidt B. Nephron 1984;36:173-182.
Gerhardt RE, Ntoso KA, Koethe JD, et al. J Am Soc Nephrol. 1992;2:1455-1458.
Frasca GM, Buscaroli A, Borgnino LC, Vangelista A. Int J Artif Organs. 1988;11:313-316.
Howard RL, Tatum K, Chan L, Shapiro JI. Dial Transplant. 1990;19:484.
Ilamathi E, Kirsch M, Moore B, Finger M. Semin Dial. 1993;6:268.
Kaplan AA. Dial Transplant. 2009;38:65.

Why Baxter Acute?

PRISMAX

Therapies

Education Resources

COVID-19 Resources